Medical insurance reimbursement conditions for bevacizumab in 2025

As of 2025, Bevacizumab (Bevacizumab) has been launched in the Chinese market and has been included in the scope of medical insurance reimbursement. For patients who meet the indications, bevacizumab can be reimbursed through Class B medical insurance, which greatly reduces the financial burden on patients. As a targeted anti-cancer drug, bevacizumab is mainly used to treat metastatic colorectal cancer, non-small cell lung cancer, ovarian cancer and other malignant tumors. Because of its significant clinical efficacy, it has become one of the important drugs in cancer treatment.

After bevacizumab is included in medical insurance, when patients purchase the drug in the hospital, they can enjoy a certain proportion of reimbursement according to the medical insurance policy, which provides a more convenient treatment path for many cancer patients. For patients who are eligible for medical insurance reimbursement, the use of bevacizumab can be partially reimbursed through medical insurance settlement. The specific reimbursement ratio usually depends on the medical insurance policy in the region and the medical institution where the patient is located.

According to the 2025 medical insurance policy, the reimbursement conditions for bevacizumab mainly include two aspects: first, the patient must meet the indications of bevacizumab, such as metastatic colorectal cancer, non-small cell lung cancer, ovarian cancer, etc.; second, the patient needs to be treated and evaluated by relevant medical institutions to confirm that the use of the drug in their treatment plan is reasonable and necessary.

Specifically, for some common cancers in the indications, patients need to meet certain treatment standards and undergo diagnosis and treatment plans by professional doctors. For example, in the treatment of metastatic colorectal cancer, bevacizumab is often used in combination with chemotherapy drugs, and this combination treatment meets the reimbursement standards set by Medicare. During treatment, patients need to undergo regular examinations to ensure the effectiveness and safety of drug treatment.

In addition to the indications of the drug itself, medical insurance reimbursement conditions may also involve the patient's age, health status and other individualized factors. Medical insurance policies in some regions may have certain restrictions on the use cycle or drug dosage. Patients need to understand the detailed requirements of local medical insurance based on specific circumstances.

Reference materials:https://www.drugs.com/bevacizumab.html